Tergus Pharma Receives 2020 Customer Value Leadership Award

Share Article

With its strong overall performance, Tergus Pharma earns Frost & Sullivan’s 2020 North America Customer Value Leadership Award in the CRO market for dermatology.

Tergus Pharma Receives 2020 Customer Value Leadership Award

"Tergus is positioning well to provide unmatched services to specialty pharma, spanning through clinical R&D to commercial manufacturing, strengthening its leadership as an outsourcing contract services provider in dermatology.”

Tergus Pharma, an end-to-end service provider for topical pharmaceutical research, drug development, testing and commercial manufacturing company, has been an industry leader for several years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality results to clients from formulation through manufacturing and is now being recognized by Frost & Sullivan for this unfailing commitment to Client satisfaction.

From the Frost & Sullivan report:

“With the contract research organization (CRO) dermatology segment constituting only 5% of the global market, specialty pharmaceutical (pharma) companies advancing topical drugs through research and development (R&D) must rely on multiple CROs at different stages to complete testing.

“Tergus Pharma (Tergus) provides full CRO services for therapeutics in dermatology. The company continually builds on technical, professional, and structural capabilities to meet customers’ performance needs, gaining a sterling worldwide reputation along the way. Additionally, Tergus’ customer-centric flexible and tailored services deliver a real partner-level engagement, regardless of project size. Always forward focused on customer’s goals and commercialization needs, the company invested in an over 100,000 square foot facility for its transition towards a full-fledged contract development and manufacturing organization. Tergus is positioning well to provide unmatched services to specialty pharma, spanning through clinical R&D to commercial manufacturing, strengthening its leadership as an outsourcing contract services provider in dermatology.”

Dr. Vijendra Nalamothu, Chairman and CEO of Tergus Pharma responded to the news by saying, “We are delighted to accept this prestigious award from Frost & Sullivan. Our focus has always been on Quality, Science and Delivery. We know if we excel in these three areas and apply this excellence to every Client interaction, every project, every time, we will continue to provide outstanding value to our customers.”

About Tergus Pharma:

Tergus Pharma is a world leading topical CDMO; FDA inspected, cGMP certified laboratory. Tergus’ topical experts have assisted with the advancement of 100’s of topical products providing R&D, release and skin testing, and manufacturing of Toxicology, Clinical trial materials and Commercial products. With the new manufacturing facility set to open in January 2021, Tergus is set to be the largest Topical CDMO in the industry. Learn more at http://www.TergusPharma.com

About Frost & Sullivan:

Frost & Sullivan is a business consulting firm involved in market research and analysis, growth strategy consulting, and corporate training across multiple industries. It is headquartered in Mountain View, California, and has 40 offices on six continents

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Susan Wingen
Tergus Pharma
+1 (919) 9081576
Email >
Visit website